The CDC expanded RSV vaccine recommendations to include adults aged 50 and above who have underlying health conditions ...

MRNA's second-quarter results are likely to spotlight a sharp decline in Spikevax sales, RSV uptake and key pipeline ...

RSV usually only has mild symptoms, but it can lead to breathing problems in the most vulnerable infants. The vaccine is offered to prevent babies contracting the virus in the first six months of ...

Moderna Inc. (NASDAQ:MRNA) reported on Friday a second-quarter loss of $2.13 per share, beating the consensus of a $2.98 loss ...

Multiple Massachusetts-based vaccine companies, including Moderna, are affected by U.S. Health and Human Services Secretary ...

Reports second quarter revenues of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.13) Updates 2025 ...

Fact checked by Jennifer Klump Adults aged 50 and older who have certain medical conditions are now eligible to get vaccinated against respiratory syncytial virus (RSV). Since the RSV vaccine was ...

Nevertheless, Moderna has lowered its revenue guidance for the year by $300 million. The company now expects to generate ...

Moderna Inc. shares are selling off Wednesday, after the Trump administration took aim at the science behind the ...

Moderna's (NASDAQ:MRNA) quarter was okay on the numbers, but the stock slid because the company pulled back its full-year ...

Moderna said it would trim roughly 10 per cent of its global workforce and have fewer than 5,000 employees by the end of the ...

HHS Secretary Robert F. Kennedy Jr. says the federal government is calling off around $500 million worth of vaccine ...